Neurotech knocked back by FDA as agency declares target condition not rare enough for special status
Neurotech International (NTI) has flagged to its shareholders that the FDA hasn't granted its product NTI164 orphan drug status.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
CGV | why suspended | 12/09/12 | 4 | 2.0K | |||
|
|||||||
CGV | looking good | 12/09/12 | 5 | 1.3K | |||
|
|||||||
CGV | Ann: Atzam 4 - Drilling Update | 11/09/12 | 36 | 6.2K | |||
|
|||||||
CGV | Ann: Appendix 3Ys - Change of Director's Inte | 11/09/12 | 8 | 1.8K | |||
|
|||||||
CGV | Ann: Atzam 4 - Drilling Update | 10/09/12 | 52 | 7.5K | |||
|
|||||||
CGV | good start | 08/09/12 | 0 | 356 | |||
|
|||||||
CGV | Ann: Appendix 3B - Issue of Director and Officer | 06/09/12 | 0 | 586 | |||
|
|||||||
CGV | Ann: Issue of Director and Officer Options | 06/09/12 | 0 | 656 | |||
|
See All Discussions